AR and prostate cancer: UBX‐390 and ARV‐110 did not induce degradation in cells transfected with the expression plasmid for AR L702H (Figure 5C).[28] UBX‐390 degraded the AR mutants most effectively, suggesting that it is a promising therapeutic option over other AR degraders or inhibitors for treating patients with drug‐resistant prostate cancers harboring AR mutations.